Are the effects of isoniaid preventive therapy and highly active antiretroviral therapy additive in preventing HIV-associated tuberculosis

 

Show simple item record

dc.contributor.author Wood, Robin
dc.contributor.author Lawn, Stephen D
dc.contributor.author Bekker, Linda-Gail
dc.date.accessioned 2018-05-08T12:56:46Z
dc.date.available 2018-05-08T12:56:46Z
dc.date.issued 2009
dc.identifier http://dx.doi.org/10.1097/QAD.0b013e32832d53e7.
dc.identifier.citation Bekker, L. G., Lawn, S. D., & Wood, R. (2009). Are the effects of isoniazid preventive therapy and highly active antiretroviral therapy additive in preventing HIV-associated tuberculosis?.
dc.identifier.uri http://hdl.handle.net/11427/28009
dc.description.abstract Golub et al. [1] recently reported a retrospective analysis of rates of incident tuberculosis (TB) in a large observational cohort of 2778 patients accessing HIV care in rural and urban South Africa. The TB incidence rate was highest [7.1/100 person-years; 95% confidence interval (CI)¼ 6.2–8.2] during the period of care when patients did not receive isoniazid preventive therapy (IPT) or highly active antiretroviral therapy (HAART). The rates were lower during person-time that accrued throughout follow-up after initiation of IPT (5.2/100 person-years; 95% CI¼ 3.4–7.8) and throughout follow-up on HAART alone (4.6/100 person-years, 95% CI¼ 3.4– 6.2). The rate was lower still (1.1/100 person-years 95% CI¼ 0.2–7.6) during person-time accrued during sequential IPT and HAART (IPTþ HAART). The authors concluded that TB risk was significantly reduced by IPT in HAART-treated adults. It was further concluded that 'the dramatic reduction in TB risk' demonstrated in this study together with supportive data from a similarly analysed study from Brazil [2] indicates that widespread use 1444 AIDS 2009, Vol 23 No 11 Fig. 1. T2-weighted flair image demonstrating enhancing lesion in the right precentral gyrus. Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. of IPT should be implemented in conjunction with the roll-out of HAART.
dc.source AIDS
dc.source.uri http://www.ncbi.nlm.nih.gov/pubmed/19564724
dc.subject.other AIDS-Related Opportunistic Infections
dc.subject.other Antitubercular Agents
dc.subject.other Epidemiologic Methods
dc.subject.other Highly Active Antiretroviral Therapy
dc.subject.other Humans
dc.subject.other Isoniazid
dc.subject.other Tuberculosis
dc.title Are the effects of isoniaid preventive therapy and highly active antiretroviral therapy additive in preventing HIV-associated tuberculosis
dc.date.updated 2016-01-22T07:59:05Z
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Institute of Infectious Disease and Molecular Medicine en_ZA
uct.type.filetype Text
uct.type.filetype Image


Files in this item

This item appears in the following Collection(s)

Show simple item record